Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
181.30
-0.68 (-0.37%)
At close: Dec 5, 2025, 4:00 PM EST
181.20
-0.10 (-0.06%)
After-hours: Dec 5, 2025, 7:40 PM EST
Biogen Market Cap
Biogen has a market cap or net worth of $26.6 billion as of December 5, 2025. Its market cap has increased by 17.43% in one year.
Market Cap
26.60B
Enterprise Value
29.23B
1-Year Change
17.43%
Ranking
Category
Stock Price
$181.30
Market Cap Chart
Since December 1, 1998, Biogen's market cap has increased from $617.50M to $26.60B, an increase of 4,207.23%. That is a compound annual growth rate of 14.94%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Dec 5, 2025 | 26.60B | 19.36% |
| Dec 31, 2024 | 22.28B | -40.57% |
| Dec 29, 2023 | 37.50B | -5.97% |
| Dec 30, 2022 | 39.88B | 13.15% |
| Dec 31, 2021 | 35.24B | -6.47% |
| Dec 31, 2020 | 37.68B | -29.63% |
| Dec 31, 2019 | 53.54B | -11.69% |
| Dec 31, 2018 | 60.63B | -10.00% |
| Dec 29, 2017 | 67.37B | 9.19% |
| Dec 30, 2016 | 61.70B | -9.65% |
| Dec 31, 2015 | 68.29B | -14.82% |
| Dec 31, 2014 | 80.16B | 21.39% |
| Dec 31, 2013 | 66.04B | 90.69% |
| Dec 31, 2012 | 34.63B | 29.54% |
| Dec 30, 2011 | 26.73B | 67.31% |
| Dec 31, 2010 | 15.98B | 3.27% |
| Dec 31, 2009 | 15.47B | 11.34% |
| Dec 31, 2008 | 13.90B | -16.78% |
| Dec 31, 2007 | 16.70B | 0.70% |
| Dec 29, 2006 | 16.58B | 7.90% |
| Dec 30, 2005 | 15.37B | -30.83% |
| Dec 31, 2004 | 22.22B | 288.89% |
| Dec 31, 2003 | 5.71B | 12.55% |
| Dec 31, 2002 | 5.08B | -51.71% |
| Dec 31, 2001 | 10.51B | 21.91% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 904.62B |
| Johnson & Johnson | 486.51B |
| AbbVie | 399.57B |
| UnitedHealth Group | 299.75B |
| AstraZeneca | 280.82B |
| Novartis AG | 255.15B |
| Merck & Co. | 247.51B |
| Abbott Laboratories | 217.50B |